Sergey Diakov
⬤ Hims & Hers Health Inc. has seen a dramatic deterioration in price action, with HIMS stock falling from around $70 to the mid-teens in approximately nine months. The selloff has unfolded amid reports of an SEC probe, an FDA crackdown, and a Novo Nordisk patent lawsuit, each adding to growing uncertainty around the telehealth company's outlook. The weekly chart shows HIMS trading near $15.82, underlining just how steep the drawdown from prior highs has been. HIMS stock tests support after prolonged decline, with analysts noting that the extended multi-month dropout has pushed price into a critical support region after sustained distribution.
⬤ The weekly price chart shows a clear and sustained downtrend, with a series of lower highs and lower lows dominating the structure. After topping above $70, price steadily declined through key intermediate support zones and is now hovering just above long-term Fibonacci levels near the 0.786 retracement in the mid-teens. Momentum indicators have weakened significantly compared with earlier phases of the rally, reflecting persistent selling pressure rather than a simple corrective pullback.
⬤ Market risks have been amplified by a wave of external developments. The Novo Nordisk patent lawsuit targets GLP-1 drug compounding, while intensifying FDA scrutiny has directly impacted the compounded weight-loss drug offerings that once powered Hims & Hers revenue growth. Citi's reported sell rating at $13.25 reinforces the bearish consensus around the name. On top of that, HIMS insiders dumped nearly $190M in shares as ownership shifts, a signal that has only deepened concerns over institutional confidence.
⬤ The sharp repricing of HIMS following its peak illustrates how quickly multi-layered pressures, both technical and fundamental, can reshape a stock's trajectory. With price now sitting near historically significant support and regulatory matters still unresolved, the path forward hinges on whether these headwinds ease or escalate. Traders and investors will want to keep a close eye on both price structure and external developments. For a deeper look at where the stock stands technically, HIMS stock slides toward $13.5 support as downtrend deepens breaks down the current setup in detail.
Sergey Diakov
